Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Clin Cancer Res. 2017 Nov 30;24(4):777–783. doi: 10.1158/1078-0432.CCR-17-1327

Figure 2. Effect of extended bevacizumab on survival in OC patients with and without mutations.

Figure 2

A. – D. Kaplan-Meier curves for progression-free and overall survival in OC patients with and without mutations in genes affecting HRR. E. – F. Adjusted hazard ratios for progression or death by individual mutation categories. Using a test of interaction, mutation status did not significantly modify the effect of extended bevacizumab on progression (0.95/0.71) = 1.33, 95% CI 0.95 – 1.85, p = 0.10.